You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

SGN-30

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Seattle (drug, other,

Recruiting
  • Recurrent Hodgkin Lymphoma
  • +3 more
  • Brentuximab Vedotin
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 4, 2022

HIV Infection, HIV-associated Hodgkin Lymphoma, Stage III Adult Hodgkin Lymphoma Trial in France (brentuximab vedotin,

Active, not recruiting
  • HIV Infection
  • +3 more
  • brentuximab vedotin
  • +3 more
  • Clamart, France
  • +5 more
Aug 11, 2022

CD30-Positive Neoplastic Cells Present, Malignant Mesothelioma Trial in Houston (Brentuximab Vedotin, Laboratory Biomarker

Recruiting
  • CD30-Positive Neoplastic Cells Present
  • Malignant Mesothelioma
  • Brentuximab Vedotin
  • Laboratory Biomarker Analysis
  • Houston, Texas
    M D Anderson Cancer Center
Jan 3, 2022

Recurrent Classic Hodgkin Lymphoma Trial in Duarte (Brentuximab Vedotin, Nivolumab)

Recruiting
  • Recurrent Classic Hodgkin Lymphoma
  • Brentuximab Vedotin
  • Nivolumab
  • Duarte, California
    City of Hope Medical Center
Feb 16, 2022

Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Duarte (Brentuximab Vedotin, Cyclosporine, Pharmacokinetic

Active, not recruiting
  • Recurrent Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Brentuximab Vedotin
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Feb 17, 2022

T Cell Lymphoma Trial in Kansas City (Brentuximab Vedotin)

Withdrawn
  • T Cell Lymphoma
  • Brentuximab Vedotin
  • Kansas City, Kansas
    The University of Kansas Cancer Center, Westwood Campus
Feb 1, 2023

Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular T-Cell

Recruiting
  • Recurrent Angioimmunoblastic T-Cell Lymphoma
  • +13 more
  • Brentuximab Vedotin
  • Pembrolizumab
  • Chicago, Illinois
    Northwestern University
Jun 15, 2022

Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma Trial (procedure, drug, biological, radiation, other)

Not yet recruiting
  • Recurrent Classic Hodgkin Lymphoma
  • Refractory Classic Hodgkin Lymphoma
  • Autologous Hematopoietic Stem Cell Transplantation
  • +13 more
  • (no location specified)
Feb 2, 2023

Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Sacramento (Bendamustine Hydrochloride, Brentuximab

Recruiting
  • Recurrent Follicular Lymphoma
  • Refractory Follicular Lymphoma
  • Bendamustine Hydrochloride
  • Brentuximab Vedotin
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Dec 17, 2021

Classic Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in United States (drug, other,

Active, not recruiting
  • Classic Hodgkin Lymphoma
  • +2 more
  • Brentuximab Vedotin
  • +2 more
  • Duarte, California
  • +5 more
Mar 17, 2022

T-Cell Lymphoma Trial (Brentuximab vedotin)

Not yet recruiting
  • T-Cell Lymphoma
  • Brentuximab vedotin
  • (no location specified)
Jun 30, 2022

Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma Trial in United

Active, not recruiting
Has Results
  • Ann Arbor Stage IB Hodgkin Lymphoma
  • +10 more
  • Brentuximab Vedotin
  • Nivolumab
  • Palo Alto, California
  • +8 more
Jul 20, 2022

Leukemia Trial in Houston (Brentuximab Vedotin, 5-Azacytidine)

Terminated
Has Results
  • Leukemia
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Sep 7, 2022

AIDS-Related Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma Trial in France, United

Active, not recruiting
  • AIDS-Related Hodgkin Lymphoma
  • +11 more
  • Brentuximab Vedotin
  • +4 more
  • La Jolla, California
  • +27 more
Jul 27, 2022

Lymphatic Diseases Trial in Italy (Brentuximab Vedotin)

Completed
  • Lymphatic Diseases
  • Brentuximab Vedotin
  • Bologna, Italy
  • +3 more
Mar 21, 2022

Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage II Primary Mediastinal (Thymic) Large

Recruiting
  • Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma
  • +3 more
  • Brentuximab Vedotin
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 10, 2022

Classic Hodgkin Lymphoma Trial (procedure, biological, drug, other, radiation)

Not yet recruiting
  • Classic Hodgkin Lymphoma
  • Biospecimen Collection
  • +19 more
  • (no location specified)
Jan 6, 2023

Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage I Nodular

Recruiting
  • Ann Arbor Stage I Hodgkin Lymphoma
  • +13 more
  • Birmingham, Alabama
  • +16 more
Nov 23, 2021

Lymphatic Diseases Trial in Italy (Brentuximab Vedotin, Bendamustine)

Terminated
  • Lymphatic Diseases
  • Bologna, BO, Italy
  • +4 more
May 26, 2021

Hodgkin Lymphoma, Peripheral T Cell Lymphoma, Anaplastic Large Cell Lymphoma Trial in United States (brentuximab vedotin)

Terminated
  • Hodgkin Lymphoma
  • +2 more
  • brentuximab vedotin
  • Anaheim, California
  • +18 more
Dec 6, 2022

Primary Cutaneous Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Cutaneous T-Cell Lymphoma Trial in Worldwide (Brentuximab

Completed
Has Results
  • Primary Cutaneous Anaplastic Large Cell Lymphoma
  • +2 more
  • Brentuximab Vedotin
  • +2 more
  • Los Angeles, California
  • +40 more
Dec 16, 2020

Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral Trial (SGN-35T)

Not yet recruiting
  • Lymphoma, T-Cell, Cutaneous
  • +5 more
  • (no location specified)
Nov 2, 2023

Colorectal Tumors, NSCLC, Squamous Cell Carcinoma of the Head and Neck Trial (SGN-EGFRd2)

Not yet recruiting
  • Colorectal Neoplasms
  • +3 more
  • (no location specified)
Aug 1, 2023

Colorectal Tumors, NSCLC, Stomach Tumors Trial (SGN-CEACAM5C)

Not yet recruiting
  • Colorectal Neoplasms
  • +5 more
  • (no location specified)
Nov 9, 2023

Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma

Terminated
Has Results
  • Adult Grade III Lymphomatoid Granulomatosis
  • +116 more
  • brentuximab vedotin
  • +2 more
  • Chicago, Illinois
  • +2 more
Aug 30, 2021